IL191791A0 - Hcv prodrug formulation - Google Patents

Hcv prodrug formulation

Info

Publication number
IL191791A0
IL191791A0 IL191791A IL19179108A IL191791A0 IL 191791 A0 IL191791 A0 IL 191791A0 IL 191791 A IL191791 A IL 191791A IL 19179108 A IL19179108 A IL 19179108A IL 191791 A0 IL191791 A0 IL 191791A0
Authority
IL
Israel
Prior art keywords
prodrug formulation
hcv
hcv prodrug
formulation
prodrug
Prior art date
Application number
IL191791A
Other versions
IL191791A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL191791A0 publication Critical patent/IL191791A0/en
Publication of IL191791A publication Critical patent/IL191791A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL191791A 2005-12-14 2008-05-28 Hcv prodrug formulation IL191791A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75014605P 2005-12-14 2005-12-14
US83059406P 2006-07-12 2006-07-12
PCT/EP2006/069262 WO2007068615A2 (en) 2005-12-14 2006-12-04 Hcv prodrug formulation

Publications (2)

Publication Number Publication Date
IL191791A0 true IL191791A0 (en) 2008-12-29
IL191791A IL191791A (en) 2011-06-30

Family

ID=37806115

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191791A IL191791A (en) 2005-12-14 2008-05-28 Hcv prodrug formulation

Country Status (21)

Country Link
US (1) US7795237B2 (en)
EP (1) EP1962808B1 (en)
JP (1) JP5649783B2 (en)
KR (1) KR20080089344A (en)
AR (1) AR058313A1 (en)
AT (1) ATE482690T1 (en)
AU (1) AU2006326130B2 (en)
BR (1) BRPI0619890A2 (en)
CA (1) CA2631498A1 (en)
CR (1) CR10026A (en)
DE (1) DE602006017257D1 (en)
DK (1) DK1962808T3 (en)
EC (1) ECSP088528A (en)
IL (1) IL191791A (en)
MA (1) MA30056B1 (en)
NO (1) NO20082563L (en)
PL (1) PL1962808T3 (en)
PT (1) PT1962808E (en)
RU (1) RU2435592C2 (en)
TW (1) TWI382840B (en)
WO (1) WO2007068615A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713514B1 (en) * 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
AU2007284615B2 (en) 2006-08-16 2011-10-27 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
ES2360538T3 (en) * 2006-09-08 2011-06-06 Johns Hopkins University COMPOSITIONS TO INCREASE TRANSPORTATION THROUGH MOCO.
ATE540672T1 (en) * 2007-03-29 2012-01-15 Hoffmann La Roche PHARMACEUTICAL COMPOSITION AND METHOD
SG173001A1 (en) 2009-01-21 2011-08-29 Hoffmann La Roche Pharmaceutical compositions comprising a hcv polymerase inhibitor prodrug
AR075180A1 (en) * 2009-01-29 2011-03-16 Novartis Ag SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
BR112012015951A2 (en) * 2010-01-28 2018-10-16 Hoffmann La Roche 4 azido nucleosides as anti-hcv compounds
BR112012028656A2 (en) 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
AR083150A1 (en) 2010-05-10 2013-02-06 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012062691A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treating hcv infections
JP5917964B2 (en) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 Tablet, tablet manufacturing method, tablet management device, tablet verification device, and program
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (en) * 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド Composition comprising a plurality of coated particles, pharmaceutical composition, pharmaceutical formulation and method of forming the particles
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP2016510000A (en) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
DE112014005175T5 (en) 2013-11-13 2016-07-21 Euro-Celtique S.A. Hydromorphone and naloxone for the treatment of pain and opioid bowel dysfunction syndrome
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3381479A1 (en) * 2017-03-29 2018-10-03 ARTOSS GmbH Carrier composition for bone substitute materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049384A1 (en) 1996-06-26 1997-12-31 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
CN1190187C (en) * 1997-10-27 2005-02-23 默克专利股份有限公司 Solid state solutions and dispersions of poorly water soluble drugs
KR100554816B1 (en) * 2001-05-03 2006-02-22 에프. 호프만-라 로슈 아게 Pharmaceutical dosage form of amorphous nelfinavir mesylate
DE10208344A1 (en) 2002-02-27 2003-09-04 Roehm Gmbh Melt extrusion of active ingredient salts
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20050044529A1 (en) 2003-08-20 2005-02-24 Microsoft Corporation Task library of task data for a plurality of components on a computer system
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form

Also Published As

Publication number Publication date
CA2631498A1 (en) 2007-06-21
TW200803873A (en) 2008-01-16
PT1962808E (en) 2010-10-29
DK1962808T3 (en) 2010-11-08
WO2007068615A2 (en) 2007-06-21
PL1962808T3 (en) 2011-03-31
TWI382840B (en) 2013-01-21
WO2007068615A3 (en) 2007-09-07
ECSP088528A (en) 2008-07-30
JP5649783B2 (en) 2015-01-07
ATE482690T1 (en) 2010-10-15
AU2006326130A1 (en) 2007-06-21
US7795237B2 (en) 2010-09-14
CR10026A (en) 2008-07-29
MA30056B1 (en) 2008-12-01
RU2435592C2 (en) 2011-12-10
DE602006017257D1 (en) 2010-11-11
AR058313A1 (en) 2008-01-30
IL191791A (en) 2011-06-30
KR20080089344A (en) 2008-10-06
NO20082563L (en) 2008-07-03
US20070202175A1 (en) 2007-08-30
JP2009519289A (en) 2009-05-14
RU2008128361A (en) 2010-01-20
BRPI0619890A2 (en) 2011-10-25
EP1962808A2 (en) 2008-09-03
AU2006326130B2 (en) 2011-09-22
EP1962808B1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
IL191791A0 (en) Hcv prodrug formulation
GB2424581B (en) Formulations
PL1879451T3 (en) Innovative formulation
EP1909584A4 (en) Prenylflavonoid formulations
IL189856A0 (en) New formulation
AP2008004547A0 (en) Petsticidal compositions
GB0503337D0 (en) Compositions
EP1877042A4 (en) Bioenhanced compositions
TWI370115B (en) New formulation
GB0526419D0 (en) Formulation
GB0505569D0 (en) Formulations
GB0501365D0 (en) Compositions
GB0517673D0 (en) Formulation
GB0501030D0 (en) Formulation
ZA200803086B (en) Bisphosphonate formulation
LT1928232T (en) Solid formulation
GB0501364D0 (en) Compositions
ZA200804974B (en) HCV prodrug formulation
GB0518952D0 (en) Bisphosphonate formulation
GB0506065D0 (en) Compositions
GB0500807D0 (en) Formulation
GB0507811D0 (en) Formulation
GB0510788D0 (en) Formulation
GB0518878D0 (en) Formulations
GB0526322D0 (en) Formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees